SEC Tracker
Get the app
OMER · XBRL financial data

Omeros financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OMER's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers——————00——1029
Cost of goods and services sold——————00——11
Research and development3229*27452423*24221619*1314
Selling, general and administrative1611*12141112*11101010*1314
Operating income (loss)(48)(40)*(39)(59)(35)(36)*(35)(32)(26)(29)*(17)0
Interest income43*3321*1——year only——
Interest expense87*8943*40(13)9*68
Income tax expense (benefit)—year only———year only00—year only00
Net income (loss)(38)(9)*(37)(56)(32)(31)*(33)(25)(31)86*5613
Earnings per share, basic USD per share(0.60)(0.15)*(0.63)(0.97)(0.56)(0.54)*(0.58)(0.43)(0.47)—0.780.18
Earnings per share, diluted USD per share——(0.63)(0.97)(0.56)—(0.58)(0.43)(0.47)—0.620.15
Weighted average shares, basic millions of shares6362*59585858*58596671*7272
Weighted average shares, diluted millions of shares——————5859——9090

Balance sheet

CSV

Fiscal quarters (OMER's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents31722234221022
Short-term investments28016522915712287482734162133130
Marketable securities280165228157122———————
Accounts receivable—————————0712
Inventory—————————001
Prepaid and other current assets5913667764876
Total current assets351218281203165134967072216180185
Property and equipment, net222223222221
Right-of-use asset19191817161514131211108
Total assets493378437356313277235201186326286287
Accounts payable6867864912556
Accrued liabilities353228282326252626292829
Total current liabilities1475359595680838681785995
Lease liability, non-current—17———12———7——
Accumulated deficit(744)(754)(791)(847)(879)(910)(944)(969)(1,000)(914)(858)(844)
Total stockholders' equity(14)(25)(71)(125)(154)(183)(214)(229)(220)(121)(63)(51)
Total liabilities and equity493378437356313277235201186326286287
Common shares outstanding (cover page) millions of shares635858585858596871727272

Cash flows

CSV

Fiscal quarters (OMER's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(38)(9)*(37)(56)(32)(31)*(33)(25)(31)86*5613
Stock-based compensation3*3*33*3*2*22*2*2*22*
Depreciation and amortization0*0*00*0*0*00*0*0*00*
Net cash from operating activities(33)*(35)*(42)(46)*(32)*(29)*(36)(22)*(18)*(40)*(15)4*
Purchases of property and equipment0*0*00*0*0*00*0*0*00*
Net cash from investing activities57*116*(62)73*36*35*3921*(7)*112*293*
Share repurchases0*5*120*0*0*00*0*0*46*
Net cash from financing activities(0)*(105)*98(27)*(5)*(4)*(2)(2)*26*(64)*(22)(7)*
Net change in cash24*(24)*(5)0*(1)*2*1(2)*0*7*(8)0*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Omeros2294.1*72.4M— 10-QJun 30, 2026
Lexicon Pharmaceuticals410.7(9.2)*445.0M20.7 quarters 10-QJun 30, 2026
XOMA Royalty86126.112.5M— 10-QMar 31, 2026
Crescent Biopharma1720(19)*37.1M8.8 quarters 10-QJun 30, 2026
4D Molecular Therapeutics703.8(70)*55.2M5.2 quarters 10-QJun 30, 2026
Lineage Cell Therapeutics371.1(7.2)*252.9M7.0 quarters 10-QJun 30, 2026
Forte Biosciences50not reported(23)*21.2M8.7 quarters 10-QJun 30, 2026
Monopar Therapeutics530*(3.2)*6.7M32.4 quarters 10-QJun 30, 2026
Editas Medicine18212(30)*153.6M7.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.